BPI 2021
Alternative Names: BPI-2021Latest Information Update: 17 Aug 2021
Price :
$50 *
At a glance
- Originator Beta Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lung cancer
Most Recent Events
- 17 Aug 2021 Beta Pharma plans a phase I trial for Lung cancer in 2022
- 04 Aug 2021 BPI 2021 is available for licensing as of 04 Aug 2021. http://betapharma.com/about-us/oncology-drug-development/
- 04 Aug 2021 Preclinical trials in Lung cancer in USA (unspecified route) (Beta Pharma pipeline, August 2021)